Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in Amsterdam
Panel on chronic conditions and off-target effects of vaccines, and a presentation on Pinion’s EBV immunotherapeutic program ROCKVILLE, Md. — Pinion Immunotherapeutics, a clinical-stage biotechnology company developing AI-designed mRNA immunotherapeutics for latent viral infections and virus-driven cancers, today announced that Chief Executive Officer Dr. Gregory Glenn will take part in two…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
